Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

The Role of Galectin-1 in Glomerular Basement Membrane Injury due to Antibody Mediated Rejection

FY 2020-21

Summary
Kidney transplantation is the best treatment for end stage kidney disease. Unfortunately, transplanted kidneys fail prematurely. The main reason for premature kidney loss is antibody mediated rejection (AMR). AMR occurs when the immune system of the recipient recognizes the transplanted organ as foreign. The recipient's immune system then attacks the graft leading to damage to all the compartments in the transplant, including the basement membranes that form scaffold for cells. This scaffold is very important as it helps cells to communicate with each other and limits the entry of immune cells. However, the mechanisms leading to injury to this scaffold in AMR are not well understood, due to the lack of good models to study it. There are also no effective treatments for AMR. In our previous study, we analyzed the distinct compartments in kidney biopsies (including the filters, called glomeruli, and the tubes which absorb fluid, called tubules) with AMR. Among multiple basement membrane molecular actors decreased in the AMR glomeruli, we found galectin-1, which was significantly increased. This is interesting because galectin-1 modifies the immune cells and binds to the basement membrane. Galectin-1 may play an important role in transplantation. My goal is to investigate the link between galectin-1 and basement membrane injury, and to test a new model of AMR. This new model is made in collaboration with biomedical engineers, and it consists of artificial glomerulus on a dish (""glomerulus-on-chip""). I will study galectin-1 in cell culture to test its effect on cells and scaffold in a simulated AMR using the glomerulus-on-chip. Galectin-1 may be a new therapeutic target for AMR. As well, our glomerulus-on-chip may address the lack of effective models to study AMR.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
449435
Name
Boshart Alexander D
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The Role of Galectin-1 in Glomerular Basement Membrane Injury due to Antibody Mediated Rejection
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Anti-Hla Antibody; Antibody Mediated Rejection; Galectin-1; Interferon Gamma; Kidney Transplant; Kidney-On-Chip; Primary Glomerular Microvascular Endothelial Cells
Abstract
Kidney transplantation is the best treatment for end stage kidney disease. Unfortunately, transplanted kidneys fail prematurely. The main reason for premature kidney loss is antibody mediated rejection (AMR). AMR occurs when the immune system of the recipient recognizes the transplanted organ as foreign. The recipient's immune system then attacks the graft leading to damage to all the compartments in the transplant, including the basement membranes that form scaffold for cells. This scaffold is very important as it helps cells to communicate with each other and limits the entry of immune cells. However, the mechanisms leading to injury to this scaffold in AMR are not well understood, due to the lack of good models to study it. There are also no effective treatments for AMR. In our previous study, we analyzed the distinct compartments in kidney biopsies (including the filters, called glomeruli, and the tubes which absorb fluid, called tubules) with AMR. Among multiple basement membrane molecular actors decreased in the AMR glomeruli, we found galectin-1, which was significantly increased. This is interesting because galectin-1 modifies the immune cells and binds to the basement membrane. Galectin-1 may play an important role in transplantation. My goal is to investigate the link between galectin-1 and basement membrane injury, and to test a new model of AMR. This new model is made in collaboration with biomedical engineers, and it consists of artificial glomerulus on a dish (""glomerulus-on-chip""). I will study galectin-1 in cell culture to test its effect on cells and scaffold in a simulated AMR using the glomerulus-on-chip. Galectin-1 may be a new therapeutic target for AMR. As well, our glomerulus-on-chip may address the lack of effective models to study AMR.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Boshart, Alexander D
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~